Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs ALT 803 (Primary) ; ETBX 011 (Primary)
- Indications Colon cancer; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors NantCell
- 04 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Sep 2017 Status changed from not yet recruiting to recruiting.
- 02 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.